The $518 million acquisition, announced in July, is expected to close Oct. 29. The stockholders’ votes approved the issuance of shares of Biovenus Class A common stock to the stockholders of Misonix.
“The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients,” Bioventus CEO Ken Reali said in an Oct. 26 news release.
